益杰立科丨 Epigenic

Public Releases Publications Events & Presentations

Epigenic Therapeutics to present preclinical update of company’s epigenome editing technology for elimination of HBV viral antigens at 2024 annual conference of the European Association for the Study of the Liver

May 10，2024

SHANGHAI, China, May 10th,2023 – Epigenic Therapeutics, a leading biotechnology company dedicated todeveloping next-generation gene modulation therapy utilizing epigenomeregulation to treat prevalent diseases, today announced acceptance of an oralpresentation at the European Association for the Study of the Liver to beheld in Milan, Italy, 5-8 June 2024. The presentation is entitled “Efficientand heritable elimination of HBV viral antigens in vivo by epigenome editing”.

Epigenic Therapeutics Raises $20 Million in Series Angel and Pre-A Funding to Advance Next Generation Gene Editing Therapy

Aug 07，2022

Epigenic Therapeutics Co., Ltd., a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for wide variety of diseases, today announced it has secured $20 million in SeriesAngel andPre-A funding.

Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development

Aug 30，2023

SHANGHAI, China, August 30th, 2023 – Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced that it has raised $32 million in Series A round of financing co-led by Qiming Venture Partners and OrbiMed, with participation from existing investor Morningside Venture Capital.